atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
Posted:
atai Life Sciences, a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced additional clinical data from the Kures Therapeutics Phase 1 trial of KUR-101 in healthy volunteers. This two-part trial was designed to assess the safety, tolerability, pharmacokinetics, and analgesic activity of KUR-101. Read more here.
New York-based Claryx has emerged from stealth with $3.5 million in pre-seed funding.
Outlander VC led the round, with participation from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford and Precursor Ventures.
The funding will help Claryx continue to "build…
Researchers have shown that measurements taken from a person's fingertip could help identify physical patterns associated with stress, anxiety and depression.
The international study, involving experts from Aston University, used a wearable device that shines light into the skin to…
Attendees
Sponsors and Exhibitors
Contact us